- Home
- AGAE vs CTSO Comparison
AGAE vs CTSO Comparison
Compare AGAE & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGAE
- CTSO
- Stock Information
- Founded
- AGAE 2017
- CTSO 1997
- Country
- AGAE United States
- CTSO United States
- Employees
- AGAE N/A
- CTSO N/A
- Industry
- AGAE Cable & Other Pay Television Services
- CTSO Medical/Dental Instruments
- Sector
- AGAE Telecommunications
- CTSO Health Care
- Exchange
- AGAE Nasdaq
- CTSO Nasdaq
- Market Cap
- AGAE 43.7M
- CTSO 51.6M
- IPO Year
- AGAE N/A
- CTSO N/A
- Fundamental
- Price
- AGAE $1.03
- CTSO $1.15
- Analyst Decision
- AGAE
- CTSO Strong Buy
- Analyst Count
- AGAE 0
- CTSO 3
- Target Price
- AGAE N/A
- CTSO $4.67
- AVG Volume (30 Days)
- AGAE 22.1K
- CTSO 147.4K
- Earning Date
- AGAE 03-26-2025
- CTSO 03-06-2025
- Dividend Yield
- AGAE N/A
- CTSO N/A
- EPS Growth
- AGAE N/A
- CTSO N/A
- EPS
- AGAE N/A
- CTSO N/A
- Revenue
- AGAE $9,256,023.00
- CTSO $37,739,531.00
- Revenue This Year
- AGAE N/A
- CTSO $9.20
- Revenue Next Year
- AGAE N/A
- CTSO $11.64
- P/E Ratio
- AGAE N/A
- CTSO N/A
- Revenue Growth
- AGAE 36.15
- CTSO 1.80
- 52 Week Low
- AGAE $0.61
- CTSO $0.70
- 52 Week High
- AGAE $1.57
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- AGAE 53.82
- CTSO 55.74
- Support Level
- AGAE $0.93
- CTSO $1.06
- Resistance Level
- AGAE $1.01
- CTSO $1.61
- Average True Range (ATR)
- AGAE 0.06
- CTSO 0.13
- MACD
- AGAE -0.01
- CTSO 0.01
- Stochastic Oscillator
- AGAE 38.70
- CTSO 29.34
About AGAE Allied Gaming & Entertainment Inc.
Allied Gaming & Entertainment Inc is an experiential entertainment company focused on providing a growing world of gamers with various experiences through renowned assets, products, and services.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.